Investigations of Long-Term Treatment with Perhexiline Maleate Using Therapeutic Monitoring and Electromyography

Publisher Website
Google Scholar
Abstract
Patients (41) taking perhexiline maleate for angina pectoris for periods of up to 70 mo., while serum concentrations of the drug was monitored, and liver function tests and electromyographic tests were made before and during treatment are reported. Severe side effects did not occur unless serum perhexiline levels were greater than 1.5 mg/l. The drug seemed effective for prolonged dosage, and the monitoring of wt, liver function test results and serum concentrations should prevent or reduce toxicity. A starting dose of 100 mg daily is recommended. The drug is not recommended for routine use in angina pectoris.